Post hoc analysis reveals radiological progression patterns in patients with HCC, suggesting durvalumab and bevacizumab may improve outcomes over placebos.
Background: EMERALD-1 (NCT03778957) met its primary endpoint, demonstrating improved PFS in pts with locoregional HCC treated with D+B+TACE vs. placebos (PBO)+TACE (stratified Cox proportional hazards hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.98. This post hoc analysis assessed outcomes by radiological progression pattern (radPP) in pts treated with D+B+TACE or PBO+TACE.
No takes yet. Share an insight, caveat, or question.
Roderburg et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: